Understanding the Genetic Determinants of Pain and Pain Management

Seminars in Oncology Nursing

Volumn 25, Issue 2 SUPPL. 1, 2009, Pages

  Miaskowski, Christine ^a  

^a NONE

Author keywords

Cancer pain; genetics; pharmacogenomics

Indexed keywords

ANALGESIC AGENT; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; MU OPIATE RECEPTOR;

ARTICLE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; HUMAN; METHODOLOGY; NEOPLASM; ONCOLOGY NURSING; PAIN;

ANALGESICS; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 ENZYME SYSTEM; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; NEOPLASMS; ONCOLOGIC NURSING; PAIN; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID, MU;

EID: 65549100226     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2009.03.012     Document Type: Article

References (28)

1. Cleeland C.S., Gonin R., Hatfield A.K., et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330 (1994) 592-596
2. Cox J.J., Reinmann F., Nicholas A.K., et al. A SCN9A channelopathy causes congenital inability to experience pain. Nature 444 (2006) 894-898
3. Dawkins J.L., Hulme D.J., Brahmbhatt S.B., et al. Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I. Nat Genet 27 (2001) 309-312
4. Bejaoui K., Wu C., Scheffler M.D., et al. SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet 27 (2001) 261-262
5. Coen K., Pareyson D., Auer-Grumbach M., et al. Novel mutations in the HSN2 gene causing hereditary sensory and autonomic neuropathy type II. Neurology 66 (2006) 748-751
6. Rubin B.Y., and Anderson S.L. The molecular basis of familial dysautonomia: overview, new discoveries and implications for directed therapies. Neuromolecular Med 10 (2008) 148-156
7. Huehne K., Zweier C., Raab K., et al. Novel missense, insertion and deletion mutations in the neurotrophic tyrosine kinase receptor type 1 gene (NTRK1) associated with congenital insensitivity to pain with anhidrosis. Neuromuscul Disord 18 (2008) 159-166
8. Minde J., Toolanen G., Andersson T., et al. Familial insensitivity to pain (HSAN V) and a mutation in the NGFB gene. A neurophysiological and pathological study. Muscle Nerve 30 (2004) 752-760
9. Fillingim R.B., Kaplan L., Staud R., et al. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 6 (2005) 159-167
10. Campa D., Gioia A., Tomei A., et al. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 83 (2008) 559-566
11. Lotsch J., Skarke C., Grosch S., et al. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12 (2002) 3-9
12. Oertel B.G., Schmidt R., Schneider A., et al. The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genom 16 (2006) 625-636
13. Chou W.Y., Yang L.C., Lu H.F., et al. Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 50 (2006) 787-792
14. Chou W.Y., Wang C.H., Liu P.H., et al. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 105 (2006) 334-337
15. Klepstad P., Rakvag T.T., Kaasa S., et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48 (2004) 1232-1239
16. Zubieta J.K., Heitzeg M.M., Smith Y.R., et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 299 (2003) 1240-1243
17. Rakvag T.T., Klepstad P., Baar C., et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116 (2005) 73-78
18. Ross J.R., Riley J., Taegetmeyer A.B., et al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer 112 (2008) 1390-1403
19. Rogers J.F., Nafziger A.N., and Bertino Jr. J.S. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 113 (2002) 746-750
20. Kadiev E., Patel V., Rad P., et al. Role of pharmacogenetics in variable response to drugs: focus on opioids. Expert Opin Drug Metab Toxicol 4 (2008) 77-91
21. Stamer U.M., and Stuber F. Genetic factors in pain and its treatment. Curr Opin Anaesthesiol 20 (2007) 478-484
22. Kirchheiner J., Schmidt H., Tzvetkov M., et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 7 (2007) 257-265
23. Totah R.A., Sheffels P., Roberts T., et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108 (2008) 363-374
24. Reyes-Gibby C.C., Shete S., Rakvag T., et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT genes. Pain 130 (2007) 25-30
25. Lotsch J., and Geisslinger G. Current evidence for a genetic modulation of the response to analgesics. Pain 121 (2006) 1-5
26. Pennisi E. Personal genomics. Number of sequenced human genomes doubles. Science 322 (2008) 838
27. Ley T.J., Mardis E.R., Ding L., et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456 (2008) 66-72
28. Ledford H. Human genes are multitaskers. Nature 456 (2008) 9